Brought to you by 
Forest licenses US rights to Recordati's lercanidipine
14 Dec 2000
Executive Summary
To enhance its cardiovascular product offerings, Forest Labs has licensed exclusive US rights to Recordati's Zanidip (lercanidipine) antihypertensive calcium-channel blocker.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forest licenses US rights to Recordati's lercanidipine
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice